Profil
- Viszeralchirurgie – Gastroenterologie – Hepatologie
- Abteilung für Endoskopie
- Transplantation
Externe Partner
ETH Zurich, Systems Biology and Laboratory of Biological Engineering; Karolinska Institutet, Department of Surgery, Stockholm; University of Geneva, Molecular Biology; University of Neuchâtel, Department of Psychology; Baveno Cooperation (EASL Research Consortium); University Hospital of Bologna, Department of Internal Medicine; University of Freiburg, Germany; Crick Institute London, UK; Harvard Medical School; Institute of Immunology and Department of Pathology University of Cambridge; Kennedy Institute, University of Oxford; Department of Radiology, Jefferson University, USA; Department of Hepatology and Liver Transplantation, Mayo Clinic Rochester, USA; Liver Unit, Hospital Clinic, Barcelona, Spain; SCCS (Swiss Hepatitis C Cohort Study); ELTR (European Liver Transplant Registry); STCS (Swiss Transplant Cohort Study); LITMUS Study, DILI Registry Study (Prospective European Drug-induced liver injury Registry); ERN Rare-Liver (European Reference Network – Rare liver diseases)
Grants
- Fondation contre le cancer, Lausanne: Pancreas Tissue Characterization by Müller Matrix Polarimetry for use in Intraoperative Diagnostics (ID) (Prof. D. Candinas, CHF 210’000)
- SF Board grant: Towards reducing infections after healthcare-associated interventions (Prof. G. Beldi, CHF 750’000)
- Innosuisse – Suisse Innovation Agency: Caldre: Cholestasis and liver disease resolved (Dr. F. Baier/Prof. D. Stroka, CHF 517’000)
- SNF Starting Grant: Macrophage Aggregation Control against Scarring (MACScar) (Prof. J. Zindel, CHF 1’790’000)
- SNF: Development of functional secretory IgA responses (Prof. A. Macpherson, CHF 1’100’000)
- Bridge – Discovery (Prof. A. Macpherson, CHF 1’561’346)
- SNF Sinergia: Understanding the role of immunometabolic imprinting for sustainable weight loss (Prof. Z. Al Nabhani CHF 1,261,612)
- SNF: Role of endothelial CCL22-CCR4 axis due to increased stiffness in chronic liver disease (Prof. A. Berzgotti, CHF 763’255)
- Gilead: SPEARHEAD (Screening imPlEmentation and linkage to cARe inHEpAtitis Delta). (Prof. N. Semmo, Prof. A. Kremer, USZ, CHF 200'000)
- Nachwuchsförderungs-Grant der Insel Gruppe AG: Feasibility Analysis of Anti-Hexokinase 1 and Anti-Kelch-like 12 Peptide as Novel Antibodies in Primary Biliary Cholangitis. (Dr. M. Kolev, CHF 80’000)